SCHEMBL22142176

SCHEMBL22142176

COCC(=O)N1CCC=C(C(C)C)[C@H]1C

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.35
GPR6 P46095 2/20 0.33
CYP2D6 P10635 4/20 0.32
CYP3A4 P08684 3/20 0.32
USP2 O75604 1/20 0.32
LMNA P02545 1/20 0.32
CHRM2 P08172 1/20 0.32
CHRM4 P08173 1/20 0.32
CHRM5 P08912 1/20 0.32
THRB P10828 1/20 0.32
CHRM1 P11229 1/20 0.32
CHRM3 P20309 1/20 0.32
SMN1; SMN2 Q16637 2/20 0.32
FHIT P49789 1/20 0.32
HIF1A Q16665 1/20 0.32
CYP1A2 P05177 1/20 0.32
BLM P54132 1/20 0.31
MCOLN3 Q8TDD5 1/20 0.31
HCRTR2 O43614 1/20 0.31
MAPT P10636 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22142175 1.00 ALDH1A1 (0.35) ALDH1A1GPR6CYP2D6CYP3A4USP2
SCHEMBL22142251 1.00 ALDH1A1 (0.35) ALDH1A1GPR6CYP2D6CYP3A4USP2
SCHEMBL22142434 0.79 SMN1; SMN2 (0.37) LMNACHRM2CHRM4CHRM5THRB
SCHEMBL22142433 0.79 SMN1; SMN2 (0.37) LMNACHRM2CHRM4CHRM5THRB
SCHEMBL22142001 0.77 BLM (0.34) ALDH1A1CYP2D6CYP3A4USP2LMNA
SCHEMBL22142008 0.77 BLM (0.34) ALDH1A1CYP2D6CYP3A4USP2LMNA
SCHEMBL22142012 0.77 BLM (0.34) ALDH1A1CYP2D6CYP3A4USP2LMNA
SCHEMBL22141980 0.66 MAOA (0.31)
SCHEMBL22141989 0.66 MAOA (0.31)
SCHEMBL22141986 0.66 MAOA (0.31)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11168093-B2 Thienopyridine inhibitors of RIPK2 CELGENE CORPORATION (US) 2021-11-09 US disclosed
US-20200199148-A1 THIENOPYRIDINE INHIBITORS OF RIPK2 CELGENE CORPORATION 2020-06-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200199148-A1 THIENOPYRIDINE INHIBITORS OF RIPK2 RIPK2, RIPK1, RIPK4 ALDH1A1 4498/4885GPR6 3457/4885CYP2D6 2953/4885
US-11168093-B2 Thienopyridine inhibitors of RIPK2 RIPK2, RIPK1, RIPK4 ALDH1A1 4498/4885GPR6 3457/4885CYP2D6 2953/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.